DK2396659T3 - RBM3-protein i testikelkræftdiagnostik og -prognostik - Google Patents

RBM3-protein i testikelkræftdiagnostik og -prognostik

Info

Publication number
DK2396659T3
DK2396659T3 DK10704927.2T DK10704927T DK2396659T3 DK 2396659 T3 DK2396659 T3 DK 2396659T3 DK 10704927 T DK10704927 T DK 10704927T DK 2396659 T3 DK2396659 T3 DK 2396659T3
Authority
DK
Denmark
Prior art keywords
prognosis
testicular cancer
cancer diagnosis
rbm3 protein
rbm3
Prior art date
Application number
DK10704927.2T
Other languages
Danish (da)
English (en)
Inventor
Karin Jirstroem
Jakob Eberhard
Original Assignee
Atlas Antibodies Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/SE2009/000091 external-priority patent/WO2009102261A1/en
Priority claimed from EP09158084A external-priority patent/EP2241889A1/en
Priority claimed from EP09167847A external-priority patent/EP2293070A1/en
Application filed by Atlas Antibodies Ab filed Critical Atlas Antibodies Ab
Application granted granted Critical
Publication of DK2396659T3 publication Critical patent/DK2396659T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/5743—Specifically defined cancers of skin, e.g. melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Reproductive Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK10704927.2T 2009-02-16 2010-02-16 RBM3-protein i testikelkræftdiagnostik og -prognostik DK2396659T3 (da)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
PCT/SE2009/000091 WO2009102261A1 (en) 2008-02-15 2009-02-16 Rbm3 as a marker for breast cancer prognosis
US16996309P 2009-04-16 2009-04-16
EP09158084A EP2241889A1 (en) 2009-04-16 2009-04-16 RBM3 protein in colorectal cancer prognostics
US23376909P 2009-08-13 2009-08-13
EP09167847A EP2293070A1 (en) 2009-08-13 2009-08-13 Means and methods for ovarian cancer prognosis
PCT/EP2009/067419 WO2010091763A1 (en) 2009-02-16 2009-12-17 Rbm3 as a marker for malignant melanoma prognosis
PCT/EP2010/051935 WO2010092187A1 (en) 2009-02-16 2010-02-16 Rbm3 protein in testicular cancer diagnostics and prognostics

Publications (1)

Publication Number Publication Date
DK2396659T3 true DK2396659T3 (da) 2013-03-04

Family

ID=41718882

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10704927.2T DK2396659T3 (da) 2009-02-16 2010-02-16 RBM3-protein i testikelkræftdiagnostik og -prognostik
DK10704928.0T DK2396660T3 (da) 2009-02-16 2010-02-16 Forudsigelse af reaktion på platinbaseret terapi

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10704928.0T DK2396660T3 (da) 2009-02-16 2010-02-16 Forudsigelse af reaktion på platinbaseret terapi

Country Status (8)

Country Link
US (3) US8632984B2 (enExample)
EP (4) EP2396657B1 (enExample)
JP (3) JP5669757B2 (enExample)
CN (1) CN102334032B (enExample)
AU (4) AU2009339802B2 (enExample)
CA (3) CA2749392A1 (enExample)
DK (2) DK2396659T3 (enExample)
WO (5) WO2010091763A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2524928A1 (en) 2011-05-18 2012-11-21 Atlas Antibodies AB RBM3 in bladder cancer
EP2396657B1 (en) * 2009-02-16 2013-11-13 Atlas Antibodies AB Rbm3 as a marker for malignant melanoma prognosis
JP2013541716A (ja) * 2010-10-22 2013-11-14 ヴァーミリオン インコーポレイテッド 卵巣癌の患者における予後予測バイオマーカー
US20120288480A1 (en) * 2011-02-22 2012-11-15 Taipei Medical University Cell population comprising orbital fat-derived stem cells (ofscs) and their isolation and applications
EP2573566A1 (en) 2011-09-20 2013-03-27 Atlas Antibodies AB RBM3 in prostate cancer prognostics
CN102590185B (zh) * 2012-01-11 2013-12-25 东南大学 以适体为识别单元的胶体晶体凝胶非标记可视化检测方法
WO2016004387A1 (en) * 2014-07-02 2016-01-07 H. Lee Moffitt Cancer Center And Research Institute, Inc. Gene expression signature for cancer prognosis
EP3023791A1 (en) * 2014-11-21 2016-05-25 Atlas Antibodies AB Predicting the responsiveness to gemcitabine treatment
CN106611094B (zh) * 2015-10-15 2021-08-06 北京寻因生物科技有限公司 基于肠道微生物菌群预测及干预化疗药物毒副反应的系统
CN113373151B (zh) * 2021-06-30 2022-05-03 华中科技大学同济医学院附属协和医院 环状RNAhsa_circ_0008399的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19932688B4 (de) 1999-07-13 2009-10-08 Scil Proteins Gmbh Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen
GB9917027D0 (en) 1999-07-20 1999-09-22 Affibody Technology Sweeden Ab In vitro selection and optional identification of polypeptides using solid support carriers
US6602670B2 (en) * 2000-12-01 2003-08-05 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on ERCC1 expression
US6686155B2 (en) * 2001-06-14 2004-02-03 Response Genetics, Inc. Method of determining a chemotherapeutic regimen based on glutathione-S-transferase pi expression
WO2006071896A2 (en) * 2004-12-23 2006-07-06 The Hong Kong University Of Science And Technology Epitope-based sars vaccine
EP1934867A2 (en) 2005-08-31 2008-06-25 Cell Signaling Technology, Inc. Reagents for the detection of protein phosphorylation in leukemia signaling pathways
WO2008051260A1 (en) 2006-01-13 2008-05-02 Battelle Memorial Institute Methods for assessing copd-retlated diseases
EP1862803A1 (en) * 2006-06-02 2007-12-05 Atlas Antibodies AB Use of protein SATB2 as a marker for colorectal cancer
EP2090890A1 (en) * 2008-02-15 2009-08-19 Atlas Antibodies AB RBM3 as a marker for breast cancer prognosis
US7902166B2 (en) 2008-04-03 2011-03-08 The Board Of Regents Of The University Of Oklahoma Compositions comprising inhibitors of RNA binding proteins and methods of producing and using same
EP2524928A1 (en) * 2011-05-18 2012-11-21 Atlas Antibodies AB RBM3 in bladder cancer
EP2396657B1 (en) * 2009-02-16 2013-11-13 Atlas Antibodies AB Rbm3 as a marker for malignant melanoma prognosis

Also Published As

Publication number Publication date
AU2009339802B2 (en) 2014-07-24
CA2749392A1 (en) 2010-08-19
JP2012518163A (ja) 2012-08-09
AU2010212772B2 (en) 2014-07-17
US8747910B2 (en) 2014-06-10
US20120034317A1 (en) 2012-02-09
WO2010091763A1 (en) 2010-08-19
EP2396346A1 (en) 2011-12-21
EP2396660B1 (en) 2013-07-24
WO2010092182A1 (en) 2010-08-19
DK2396660T3 (da) 2013-10-28
EP2396659A1 (en) 2011-12-21
JP5767116B2 (ja) 2015-08-19
WO2010092190A3 (en) 2010-11-04
WO2010092187A1 (en) 2010-08-19
AU2009339802A1 (en) 2011-07-28
US8632984B2 (en) 2014-01-21
HK1166371A1 (en) 2012-10-26
EP2396346B1 (en) 2013-04-03
EP2396660A2 (en) 2011-12-21
AU2010212764A1 (en) 2011-07-28
CN102334032A (zh) 2012-01-25
AU2010212772A1 (en) 2011-07-28
AU2010212769C1 (en) 2014-10-09
EP2396657A1 (en) 2011-12-21
AU2010212769B2 (en) 2014-07-17
AU2010212769A1 (en) 2011-07-28
WO2010092190A2 (en) 2010-08-19
CN102334032B (zh) 2015-01-28
CA2749349A1 (en) 2010-08-19
JP2012518164A (ja) 2012-08-09
US20120269764A1 (en) 2012-10-25
JP5611986B2 (ja) 2014-10-22
EP2396659B1 (en) 2012-11-21
AU2010212764B2 (en) 2014-07-17
US20120058202A1 (en) 2012-03-08
CA2749350A1 (en) 2010-08-19
EP2396657B1 (en) 2013-11-13
WO2010092184A1 (en) 2010-08-19
JP5669757B2 (ja) 2015-02-18
JP2012518162A (ja) 2012-08-09

Similar Documents

Publication Publication Date Title
DK2396659T3 (da) RBM3-protein i testikelkræftdiagnostik og -prognostik
NL350111I2 (nl) fenpicoxamid en prothioconazool
IL254144A0 (en) Methods for reprogramming cells and uses thereof
EP2519874A4 (en) METHOD AND SYSTEM FOR CONNECTION PROCESSING
GB0906458D0 (en) Macromolecules for diagnosis and prognosis
BRPI1004572A2 (pt) "fusões genéticas recorrentes em câncer
HRP20160737T1 (hr) Anti-her3-protutijela i njihove uporabe
EP2379922A4 (en) Valve system
EP2593795A4 (en) DIAGNOSIS FOR DARM CANCER
EP2547888A4 (en) TREATMENT OF FUEL AND WATER
SI2435432T2 (sl) Sredstva, ki inducirajo apoptozo, za zdravljenje raka in imunskih in avtoimunskih bolezni
SI2560653T1 (sl) Določeni aminopirimidini, sestavki le-teh in postopki za njihovo uporabo
IT1400121B1 (it) Copoliestere alifatico-aromatico e sue miscele.
EP2466932A4 (en) INVOICING SYSTEM AND METHOD
DK2624866T3 (da) Tumorspecifikke antistoffer og anvendelser deraf
HUE037163T2 (hu) Hemoglobin készítmények
HUE036081T2 (hu) Mirac proteinek
ZA201207574B (en) Phytocannabinoids in the treatment of cancer
PL2366031T3 (pl) Metody sekwencjonowania w diagnostyce prenatalnej
IL220386B (en) Compositions for the liquidation of tumors and uses thereof
IL236516A0 (en) Methods and compositions for diagnosis and treatment of cancer
HRP20170225T1 (hr) Fosfoplatini i njihova uporaba za liječenje karcinoma
FI20095396A7 (fi) Alus
DK2563935T3 (da) In situ-hybridiseringsfremgangsmåde og -buffer
SG10201506437PA (en) BARD1 Isoforms in Lung and Colorectal Cancer and Use Thereof